Literature DB >> 116188

Inhibitory effect of cystic fibrosis serum on pseudomonas phagocytosis by rabbit and human alveolar macrophages.

M J Thomassen, B Boxerbaum, C A Demko, P J Kuchenbrod, D G Dearborn, R E Wood.   

Abstract

This report presents experimental observations indicating the presence of an inhibitory activity in cystic fibrosis (CF) serum which impairs phagocytosis of Pseudomonas aeruginosa by rabbit as well as human alveolar macrophages. Of the 49 patient serum samples studied, 40 consistently showed greater than or equal to 60% inhibition, 3 showed no inhibition and 6 were in the range of 20-60% inhibition of Pseudomonas phagocytosis. In parallel studies, the phagocytosis of S. aureus and S. marcescens was found not to be inhibited by CF serum. Mixing of CF serum with normal serum could not overcome the inhibitory effect, indicating the presence of an inhibitory factor rather than the lack of a necessary component. The inhibitory activity is not lost upon exposure of serum to glass, upon freezing the serum once, or upon heating at 56 degrees C for 30 minutes.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 116188     DOI: 10.1203/00006450-197909000-00030

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  19 in total

1.  Inhibition of high-mobility group box 1 protein (HMGB1) enhances bacterial clearance and protects against Pseudomonas Aeruginosa pneumonia in cystic fibrosis.

Authors:  Maria Entezari; Daniel J Weiss; Ravikumar Sitapara; Laurie Whittaker; Matthew J Wargo; JianHua Li; Haichao Wang; Huan Yang; Lokesh Sharma; Binh D Phan; Mohammad Javdan; Sangeeta S Chavan; Edmund J Miller; Kevin J Tracey; Lin L Mantell
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

Review 2.  Inflammation in the lung in cystic fibrosis. A vicious cycle that does more harm than good?

Authors:  M Berger
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

3.  Association with phagocytic inhibition of anti-Pseudomonas aeruginosa immunoglobulin G antibody subclass levels in serum from patients with cystic fibrosis.

Authors:  T R Shryock; J S Mollé; J D Klinger; M J Thomassen
Journal:  J Clin Microbiol       Date:  1986-03       Impact factor: 5.948

4.  Microtiter immunoenzymatic assay (micro-ELISA) for antigen-specific IgG4 subclass antibody.

Authors:  Y P Hsu; R B Moss
Journal:  Clin Rev Allergy       Date:  1983-06

5.  Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses.

Authors:  I Eichler; L Joris; Y P Hsu; J Van Wye; R Bram; R Moss
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

6.  Pulmonary cellular response to chronic irritation and chronic Pseudomonas aeruginosa pneumonia in cats.

Authors:  M J Thomassen; J D Klinger; G B Winnie; R E Wood; C Burtner; J F Tomashefski; J G Horowitz; B Tandler
Journal:  Infect Immun       Date:  1984-09       Impact factor: 3.441

Review 7.  Cystic fibrosis. Infection and immunity to Pseudomonas.

Authors:  R U Sorensen; R L Waller; J D Klinger
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

Review 8.  Microbiology of airway disease in patients with cystic fibrosis.

Authors:  P H Gilligan
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

9.  Cystic fibrosis pseudomonas opsonins. Inhibitory nature in an in vitro phagocytic assay.

Authors:  R B Fick; G P Naegel; R A Matthay; H Y Reynolds
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

10.  Serum bactericidal effect on Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Authors:  M J Thomassen; C A Demko
Journal:  Infect Immun       Date:  1981-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.